ValuEngine Bows Chinese-Language Reports

The analysis provider has begun providing its stock reports and newsletters in Chinese, in part via an agreement with online broker SogoTrade.

fake-research-report-image

ValuEngine produces 12-page PDF reports every day for around 4,100 US stocks using two distinct models—a valuation model, and a forecast model that uses the valuation model but also delivers short- and long-term forecasts of whether a stock is over- or under-valued. The vendor then uses the outputs of these models to create market strategies. The reports are distributed via third parties, including Thomson Reuters, Bloomberg, Markit, ConvergEx Jaywalk and S&P Global Market Intelligence (formerly

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: http://subscriptions.waterstechnology.com/subscribe

You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Waterstechnology? View our subscription options

CME: CFTC OKs clearing move to Google Cloud

The CFTC has given the Chicago-based exchange approval to run its clearing and settlement infrastructure on the Google Cloud Platform, while the exchange and vendor have extended their partnership to last until at least 2037.

Once a blockchain cheerleader, Axoni changes its playbook

The fintech, whose origins can be traced back to the genesis of capital markets’ complicated flirtation with DLT, has largely ditched the tech as the foundation of its data synchronization offering, opting for more familiar territory.

Most read articles loading...

You need to sign in to use this feature. If you don’t have a WatersTechnology account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here